34,175 Shares in Lifecore Biomedical, Inc. $LFCR Acquired by Boston Partners

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Boston Partners acquired a new position in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 34,175 shares of the company's stock, valued at approximately $241,000. Boston Partners owned 0.09% of Lifecore Biomedical as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in LFCR. Geode Capital Management LLC lifted its stake in shares of Lifecore Biomedical by 14.7% in the 4th quarter. Geode Capital Management LLC now owns 685,746 shares of the company's stock worth $5,097,000 after purchasing an additional 88,061 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Lifecore Biomedical by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after purchasing an additional 3,012 shares during the period. Invesco Ltd. bought a new position in shares of Lifecore Biomedical in the 4th quarter worth approximately $4,128,000. Barclays PLC lifted its stake in shares of Lifecore Biomedical by 13.5% in the 4th quarter. Barclays PLC now owns 33,972 shares of the company's stock worth $253,000 after purchasing an additional 4,028 shares during the period. Finally, MetLife Investment Management LLC bought a new position in shares of Lifecore Biomedical during the 4th quarter valued at approximately $108,000. Institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Stock Performance

Shares of NASDAQ:LFCR traded up $0.38 during mid-day trading on Friday, reaching $7.60. 119,681 shares of the company traded hands, compared to its average volume of 116,304. The company's 50 day moving average price is $7.58 and its 200-day moving average price is $6.81. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.84 and a quick ratio of 1.77. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $8.85. The firm has a market cap of $284.30 million, a PE ratio of -5.80 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%.The business had revenue of $36.44 million during the quarter, compared to analysts' expectations of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS. On average, equities analysts expect that Lifecore Biomedical, Inc. will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Aron R. English sold 1,139,504 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $6.50, for a total value of $7,406,776.00. Following the transaction, the insider directly owned 414,599 shares of the company's stock, valued at approximately $2,694,893.50. The trade was a 73.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 32.20% of the company's stock.

Wall Street Analysts Forecast Growth

LFCR has been the subject of a number of recent research reports. William Blair initiated coverage on Lifecore Biomedical in a research note on Wednesday, May 21st. They set an "outperform" rating for the company. Wall Street Zen upgraded Lifecore Biomedical from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Lifecore Biomedical currently has an average rating of "Moderate Buy" and a consensus target price of $8.00.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.